Quantcast
Last updated on April 20, 2014 at 8:10 EDT

Latest Papillary thyroid cancer Stories

2014-02-03 00:21:05

WOODCLIFF LAKE, N.J., Feb. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). The preliminary safety analyses showed that the five most common adverse reactions were hypertension,...

2013-10-09 11:47:30

Findings from the first study to show a specific function of the immune system in the proliferation of thyroid cancer may ultimately change the course of treatment Researchers at the National Institutes of Health (NIH), Bethesda, MD, have taken the first steps to determine if a protein, called Programmed Death Ligand 1 (PD-L1), can help to predict which thyroid cancer patients will most likely have a recurrence of the disease. Study findings were presented today at the 2013 Clinical...

2013-09-30 10:15:46

Tumor genetics, cancer cell signaling discoveries pave way for use of new therapies For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels. Two recent clinical trials led by a researcher from...

2013-04-10 13:33:05

Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue. "Papillary thyroid cancer is the most common endocrine...

2013-02-14 08:28:58

WOODCLIFF LAKE, N.J., Feb. 14, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the treatment,...

2013-02-04 08:26:36

BURLINGTON, Mass., Feb. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the United States and Europe due to the expected approval of several new therapies. In addition to Exelixis's Cometriq (cabozantinib) for advanced medullary thyroid carcinomas (MTC)--which was approved in the U.S. late last...

2012-06-11 20:35:05

Study finds that the majority of patients with thyroid cancer, except for those in the most advanced stage, continue to have the same chance of survival as those who are disease-free Research presented at the Society of Nuclear Medicine's 59th Annual Meeting reveals that patients with differentiated thyroid cancer live as long as people in perfect health, unless they are in the minority and have reached the most advanced stages of disease. Survival did not vary based on age, sex, or even...

2012-05-22 08:37:40

A review of medical records of patients treated at an academic tertiary care center suggests that obese patients present to their physicians with more advanced stage and more aggressive forms of papillary thyroid cancer (PTC), according to a report published Online First by Archives of Surgery, a JAMA Network publication. Thyroid cancer is on the rise on the United States and most of the increase is due to PTC, although the authors write that it is debatable whether the increase is caused...

2012-05-03 18:43:21

The use of single positron emission computed tomography (SPECT)/computed tomography (CT) has been reported to change clinical management in a significant number of thyroid cancer patients according to research presented in the May issue of The Journal of Nuclear Medicine. Information obtained from these scans not only helps determine the need for radioiodine therapy or alterative options, but also impacts the long-term follow-up strategy. “In this article I aimed to highlight the...

2012-03-29 22:10:17

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumor recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI. "Because papillary renal cell carcinoma (pRCC) only affects ten to 15% of kidney cancer patients, the small number of patients enrolled in individual studies makes it hard to draw meaningful...